| Name | Title | Contact Details |
|---|---|---|
Nicole Thai |
Vice President, Information Technology | Profile |
Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.
harmagreen is a company focused on BIOTECH SCIENCES utilizing proprietary technologies and formulations in its state of the art CANNABIS BOTANY CENTER
Thomson Research Associates is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ology Bioservices is a private, American biopharmaceutical company headquartered in Alachua, Florida.
Advance Nanotech Inc is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.